Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond

Current therapy for Anderson–Fabry disease in Poland includes hospital or clinic-based intravenous enzyme replacement therapy with recombinant agalsidase alpha or beta, or oral pharmacological chaperone therapy with migalastat. Some countries around the world offer such treatment to patients in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowicki, Michał, Bazan-Socha, Stanisława, Kłopotowski, Mariusz, Błażejewska-Hyżorek, Beata, Kusztal, Mariusz, Pawlaczyk, Krzysztof, Sławek, Jarosław, Oko, Andrzej, Oko-Sarnowska, Zofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394954/
https://www.ncbi.nlm.nih.gov/pubmed/34443990
http://dx.doi.org/10.3390/ijerph18168242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394954/
https://www.ncbi.nlm.nih.gov/pubmed/34443990
http://dx.doi.org/10.3390/ijerph18168242

Ejemplares similares